Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough chest tumors: targeted radiation trial launches

NCT ID NCT06603987

Disease control Sponsor: Stella Pharma Corporation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new type of radiation therapy called BNCT for people with chest tumors that have come back and cannot be removed by surgery or treated with standard methods. About 30 participants will receive a special boron drug followed by neutron radiation to target cancer cells while sparing healthy organs. The goal is to see if this approach is safe and can control tumor growth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Oct 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Written informed consent must be obtained from the subject. * Patients with histopathological diagnosed malignant tumor (except cutaneous angiosarcoma) * Measurable disease, as defined by RECIST v1.1. * Patients diagnosed with recurrent malignant tumors that are unresectable and perceived challenging to treat with standard treatment. * Patients with ECOG performance status score of 0 or 1. Exclusion Criteria: * Patients with active disease or active double cancers other than target lesions. * Patients with imaging findings that affect imaging evaluation of the tumor, such as ground-glass opacities * Patients who received radiation therapy exceeding 65 Gy as a prior treatment for the target lesion. * Any serious concomitant disease that precludes completion of the study treatment. * Patients with remaining complications of Grade 3 or higher related to prior radiation therapy in the irradiation field.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thoracic solid malignant tumor are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast neoplasm Esophageal Neoplasms Mesothelioma, Malignant neurofibrosarcoma non-small cell lung carcinoma thoracic cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Thoracic solid malignant tumor

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ORIX Kouraibashi Bldg. 8F 3-2-7 Kouraibashi Chuo-ku

    Osaka, Osaka, 541-0043, Japan